By Dr. Natalie Howard, DNP, MSN, APRN, MBA — Johns Hopkins · Metabolic Medicine
When you stop a GLP-1 medication like semaglutide or tirzepatide, you regain most — but not all — of the weight you lost, usually within about a year. This happens because obesity behaves like a chronic disease: remove the treatment and the underlying biology reasserts, much the way blood pressure climbs after stopping an antihypertensive. The newest 2026 trial evidence shows that a lower maintenance dose can preserve much of the loss, which means stopping completely is no longer the only option.
How much weight do you regain after stopping a GLP-1?
Across the major trials, people regain roughly two-thirds of their lost weight within a year of stopping. In the 2026 SURMOUNT-MAINTAIN trial (Horn DB, et al. Lancet. 2026; PMID 42119587), participants who came off tirzepatide held a 9.9% net loss from their starting weight at week 112, compared with 21.9% for those who stayed on the highest tolerated dose. On the semaglutide side, the STEP 1 trial extension (Wilding JPH, et al. Diabetes Obes Metab. 2022;24(8):1553–1564; PMID 35441470) saw participants regain two-thirds of their loss and settle at about 5.6% net one year after withdrawal.
The honest takeaway is in that word most — not all. Every stop group in these trials still held a meaningful net loss, and results vary widely from person to person. The fear-based version online (“you gain it all back, the drug ruins your metabolism”) overstates what the data actually shows.
Why does the weight come back?
Because a GLP-1 medication treats the biology of appetite and energy regulation only while it is in your system. These drugs act on the brain’s hunger and fullness signaling and help lower the body’s defended weight “set point.” Remove the medication, and that signaling drifts back toward where it started, intake rises, and weight follows.
The STEP 1 investigators put it as plainly as it can be put: their findings confirm the chronicity of obesity and that ongoing treatment is required to maintain the improvement. In other words, regain is the disease reasserting once treatment stops — not evidence that the medication damaged your metabolism.
Does stopping reverse the health benefits too?
Largely, yes — and the cardiometabolic markers move alongside the weight. A 2025 post hoc analysis of the SURMOUNT-4 trial (Horn DB, et al. JAMA Intern Med. 2025; doi:10.1001/jamainternmed.2025.6112) found that among people who stopped tirzepatide and regained at least 25% of their lost weight within a year, the improvements in waist circumference, cholesterol, and fasting insulin reversed too.
The original SURMOUNT-4 withdrawal trial (Aronne LJ, et al. JAMA. 2024;331(1):38–48; doi:10.1001/jama.2023.24945) showed the same pattern at the level of weight: people who continued tirzepatide lost an additional 5.5%, while those switched to placebo regained 14.0% — a roughly 20-point swing that came down entirely to whether treatment continued. The semaglutide STEP 4 trial (Rubino D, et al. JAMA. 2021;325(14):1414–1425; PMID 33755728) tells the same story: continuing meant losing about 7.9% more, while switching to placebo meant regaining about 6.9%.
Two drugs, four trials, one consistent pattern.
Is there a way to keep the weight off without staying on the full dose?
This is the genuinely new finding. SURMOUNT-MAINTAIN tested a reduced 5 mg maintenance dose against both the full dose and placebo. The 5 mg group held a 16.6% net loss at week 112 — between the full-dose group (21.9%) and the stop group (9.9%). And among participants who regained at least half of their lost weight and needed a rescue dose, the split was striking: 8% on the full dose, 25% on 5 mg, and 67% on placebo.
What that means in practice: stepping down to a lower maintenance dose is now an evidence-based middle path, not guesswork. All-or-nothing is no longer the only choice.
Do you have to take a GLP-1 forever?
Not necessarily forever — but it is best approached the way you would any chronic condition: as long-term management rather than a short course. Going in expecting “a few months and I’m done” sets up the exact regain these trials describe.
If cost, supply, or side effects are pushing you toward stopping, it is worth taking the time to discuss a lower maintenance dose with a clinician before quitting outright. And if you do stop, stop deliberately and with a plan — not by running out. The regain is not a moral failure and it is not your metabolism breaking. It is predictable biology you can plan around.
The bottom line
Stopping a GLP-1 tends to bring back most of your lost weight, along with much of the metabolic benefit, because obesity is a chronic disease that reasserts when treatment ends. But you do not bounce all the way back, the effect varies from person to person, and as of 2026 there is real trial evidence for a lower maintenance dose as a way to keep more of what you gained. The useful question was never “will I regain it” — it is “what kind of condition am I treating, and for how long.”
Frequently asked questions
Will I gain back all the weight if I stop a GLP-1?
No. Every stop group in these trials held a meaningful net loss; results vary widely by person. “Most, on average, if you stop cold” is accurate — “all of it” is not.
Is weight regain a sign the drug damaged my metabolism?
No. Regain reflects the chronic nature of obesity reasserting once treatment stops, the same way blood pressure rises after stopping an antihypertensive.
Can I switch to a lower dose instead of quitting?
New 2026 data (SURMOUNT-MAINTAIN) supports a 5 mg tirzepatide maintenance dose as a middle path. Raise it with your prescriber.
How fast does weight regain happen after stopping?
Most regain occurs over roughly the first year off treatment.
Does this apply to both Ozempic/Wegovy and Mounjaro/Zepbound?
Yes. The pattern held across both semaglutide (STEP trials) and tirzepatide (SURMOUNT trials).
Sources
- Horn DB, Aronne LJ, Wharton S, et al. Tirzepatide for maintenance of bodyweight reduction (SURMOUNT-MAINTAIN). Lancet. 2026 May 12. doi:10.1016/S0140-6736(26)00656-2. PMID 42119587. NCT06047548.
- Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–1564. doi:10.1111/dom.14725. PMID 35441470.
- Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction (SURMOUNT-4). JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945. NCT04660643.
- Horn DB, Linetzky B, Davies MJ, et al. Cardiometabolic parameter change by weight regain on tirzepatide withdrawal: post hoc analysis of SURMOUNT-4. JAMA Intern Med. 2025 Nov 24. doi:10.1001/jamainternmed.2025.6112.
- Rubino D, Abrahamsson N, Davies M, et al. Effect of continued weekly semaglutide vs placebo on weight loss maintenance (STEP 4). JAMA. 2021;325(14):1414–1425. doi:10.1001/jama.2021.3224. PMID 33755728.
This article is educational and is not medical advice. Talk with your own clinician about your treatment. Portions of the companion video use an AI-generated presenter.